Posaconazole oral suspension primary prophylaxis in acute leukemia and allogeneic stem cell transplant patients

can it be used without measurement of plasma concentration?

Corrado Girmenia, Luciana Annino, B. Mariotti, R. Fanci, Clara Minotti, Antonio Spadea, A. Carotti, Monica Piedimonte, A. Chierichini, Elisabetta Cerchiara, Desiree Caselli, L. Cupelli, Francesco Arcioni, Alice Bertaina, Michela Ribersani, A. Proia, Andrea Mengarelli, Vincenzo Perriello, Giovanni Fernando Torelli, M. Di Gioia & 4 others Maria Ilaria Del Principe, Maria Iris Cassetta, Stefania Fallani, Andrea Novelli

Research output: Contribution to journalArticle

Abstract

Posaconazole oral suspension (PCZ-susp) can display a variable degree of inter and intra-individual absorption. However, there is no agreement on the need of plasma-posaconazole-concentration (PPC) monitoring as a routine practice in patients receiving PCZ-susp. In this prospective, multicenter study we evaluated the variability of PPCs in hematologic patients receiving PCZ-susp prophylaxis with the aim to define conditions at different risk of subtherapeutic PPCs. Overall, 103 acute leukemia (AL) patients submitted to intensive chemotherapy (115 courses) and 46 allogeneic stem cell transplant (allo-SCT) recipients (47 courses) receiving PCZ-susp prophylaxis were considered. The adequacy of PPC pattern after the steady state (≥day 7 of treatment) in courses with two or more PPC measurements was defined as follows: inadequate pattern: PPC

Original languageEnglish
Pages (from-to)445-458
Number of pages14
JournalMedical Mycology
Volume54
Issue number5
DOIs
Publication statusPublished - Jul 1 2016

Fingerprint

leukemia
stem cells
mouth
Suspensions
disease control
Leukemia
Stem Cells
Transplants
prospective studies
drug therapy
posaconazole
monitoring
Multicenter Studies
Prospective Studies
Drug Therapy

Keywords

  • acute leukemia
  • allogeneic stem cell transplant
  • diarrhea
  • plasma level
  • posaconazole

ASJC Scopus subject areas

  • veterinary(all)
  • Infectious Diseases

Cite this

Posaconazole oral suspension primary prophylaxis in acute leukemia and allogeneic stem cell transplant patients : can it be used without measurement of plasma concentration? / Girmenia, Corrado; Annino, Luciana; Mariotti, B.; Fanci, R.; Minotti, Clara; Spadea, Antonio; Carotti, A.; Piedimonte, Monica; Chierichini, A.; Cerchiara, Elisabetta; Caselli, Desiree; Cupelli, L.; Arcioni, Francesco; Bertaina, Alice; Ribersani, Michela; Proia, A.; Mengarelli, Andrea; Perriello, Vincenzo; Torelli, Giovanni Fernando; Di Gioia, M.; Del Principe, Maria Ilaria; Cassetta, Maria Iris; Fallani, Stefania; Novelli, Andrea.

In: Medical Mycology, Vol. 54, No. 5, 01.07.2016, p. 445-458.

Research output: Contribution to journalArticle

Girmenia, C, Annino, L, Mariotti, B, Fanci, R, Minotti, C, Spadea, A, Carotti, A, Piedimonte, M, Chierichini, A, Cerchiara, E, Caselli, D, Cupelli, L, Arcioni, F, Bertaina, A, Ribersani, M, Proia, A, Mengarelli, A, Perriello, V, Torelli, GF, Di Gioia, M, Del Principe, MI, Cassetta, MI, Fallani, S & Novelli, A 2016, 'Posaconazole oral suspension primary prophylaxis in acute leukemia and allogeneic stem cell transplant patients: can it be used without measurement of plasma concentration?', Medical Mycology, vol. 54, no. 5, pp. 445-458. https://doi.org/10.1093/mmy/myw001
Girmenia, Corrado ; Annino, Luciana ; Mariotti, B. ; Fanci, R. ; Minotti, Clara ; Spadea, Antonio ; Carotti, A. ; Piedimonte, Monica ; Chierichini, A. ; Cerchiara, Elisabetta ; Caselli, Desiree ; Cupelli, L. ; Arcioni, Francesco ; Bertaina, Alice ; Ribersani, Michela ; Proia, A. ; Mengarelli, Andrea ; Perriello, Vincenzo ; Torelli, Giovanni Fernando ; Di Gioia, M. ; Del Principe, Maria Ilaria ; Cassetta, Maria Iris ; Fallani, Stefania ; Novelli, Andrea. / Posaconazole oral suspension primary prophylaxis in acute leukemia and allogeneic stem cell transplant patients : can it be used without measurement of plasma concentration?. In: Medical Mycology. 2016 ; Vol. 54, No. 5. pp. 445-458.
@article{ba0296ffac564f63ab85063019d5e60b,
title = "Posaconazole oral suspension primary prophylaxis in acute leukemia and allogeneic stem cell transplant patients: can it be used without measurement of plasma concentration?",
abstract = "Posaconazole oral suspension (PCZ-susp) can display a variable degree of inter and intra-individual absorption. However, there is no agreement on the need of plasma-posaconazole-concentration (PPC) monitoring as a routine practice in patients receiving PCZ-susp. In this prospective, multicenter study we evaluated the variability of PPCs in hematologic patients receiving PCZ-susp prophylaxis with the aim to define conditions at different risk of subtherapeutic PPCs. Overall, 103 acute leukemia (AL) patients submitted to intensive chemotherapy (115 courses) and 46 allogeneic stem cell transplant (allo-SCT) recipients (47 courses) receiving PCZ-susp prophylaxis were considered. The adequacy of PPC pattern after the steady state ({\^a}‰¥day 7 of treatment) in courses with two or more PPC measurements was defined as follows: inadequate pattern: PPC",
keywords = "acute leukemia, allogeneic stem cell transplant, diarrhea, plasma level, posaconazole",
author = "Corrado Girmenia and Luciana Annino and B. Mariotti and R. Fanci and Clara Minotti and Antonio Spadea and A. Carotti and Monica Piedimonte and A. Chierichini and Elisabetta Cerchiara and Desiree Caselli and L. Cupelli and Francesco Arcioni and Alice Bertaina and Michela Ribersani and A. Proia and Andrea Mengarelli and Vincenzo Perriello and Torelli, {Giovanni Fernando} and {Di Gioia}, M. and {Del Principe}, {Maria Ilaria} and Cassetta, {Maria Iris} and Stefania Fallani and Andrea Novelli",
year = "2016",
month = "7",
day = "1",
doi = "10.1093/mmy/myw001",
language = "English",
volume = "54",
pages = "445--458",
journal = "Medical Mycology",
issn = "1369-3786",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Posaconazole oral suspension primary prophylaxis in acute leukemia and allogeneic stem cell transplant patients

T2 - can it be used without measurement of plasma concentration?

AU - Girmenia, Corrado

AU - Annino, Luciana

AU - Mariotti, B.

AU - Fanci, R.

AU - Minotti, Clara

AU - Spadea, Antonio

AU - Carotti, A.

AU - Piedimonte, Monica

AU - Chierichini, A.

AU - Cerchiara, Elisabetta

AU - Caselli, Desiree

AU - Cupelli, L.

AU - Arcioni, Francesco

AU - Bertaina, Alice

AU - Ribersani, Michela

AU - Proia, A.

AU - Mengarelli, Andrea

AU - Perriello, Vincenzo

AU - Torelli, Giovanni Fernando

AU - Di Gioia, M.

AU - Del Principe, Maria Ilaria

AU - Cassetta, Maria Iris

AU - Fallani, Stefania

AU - Novelli, Andrea

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Posaconazole oral suspension (PCZ-susp) can display a variable degree of inter and intra-individual absorption. However, there is no agreement on the need of plasma-posaconazole-concentration (PPC) monitoring as a routine practice in patients receiving PCZ-susp. In this prospective, multicenter study we evaluated the variability of PPCs in hematologic patients receiving PCZ-susp prophylaxis with the aim to define conditions at different risk of subtherapeutic PPCs. Overall, 103 acute leukemia (AL) patients submitted to intensive chemotherapy (115 courses) and 46 allogeneic stem cell transplant (allo-SCT) recipients (47 courses) receiving PCZ-susp prophylaxis were considered. The adequacy of PPC pattern after the steady state (≥day 7 of treatment) in courses with two or more PPC measurements was defined as follows: inadequate pattern: PPC

AB - Posaconazole oral suspension (PCZ-susp) can display a variable degree of inter and intra-individual absorption. However, there is no agreement on the need of plasma-posaconazole-concentration (PPC) monitoring as a routine practice in patients receiving PCZ-susp. In this prospective, multicenter study we evaluated the variability of PPCs in hematologic patients receiving PCZ-susp prophylaxis with the aim to define conditions at different risk of subtherapeutic PPCs. Overall, 103 acute leukemia (AL) patients submitted to intensive chemotherapy (115 courses) and 46 allogeneic stem cell transplant (allo-SCT) recipients (47 courses) receiving PCZ-susp prophylaxis were considered. The adequacy of PPC pattern after the steady state (≥day 7 of treatment) in courses with two or more PPC measurements was defined as follows: inadequate pattern: PPC

KW - acute leukemia

KW - allogeneic stem cell transplant

KW - diarrhea

KW - plasma level

KW - posaconazole

UR - http://www.scopus.com/inward/record.url?scp=84981714812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84981714812&partnerID=8YFLogxK

U2 - 10.1093/mmy/myw001

DO - 10.1093/mmy/myw001

M3 - Article

VL - 54

SP - 445

EP - 458

JO - Medical Mycology

JF - Medical Mycology

SN - 1369-3786

IS - 5

ER -